REG - N4 Pharma PLC - Notification of Intention to Grant Patent

N4 PharmaAnnouncement

11/02/2021 10:30

RNS Number : 8017O
  
N4 Pharma PLC
  
11 February 2021
  
 

11 February 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
 
Notification of Intention to Grant Patent
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that the University of Queensland ("UQ") has been notified by the European Patent Office ("EPO") of its intention to grant a European Patent in relation to Nuvec® specifically in respect of its composition, particulate materials and methods for making the particulate materials (the "Patent"). N4 Pharma has the exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals.
 
Having received the notification the next steps prior to formal grant will require UQ to confirm the particulars and translations with the EPO prior to publication of the grant after which the Patent will be validated on a country by country basis throughout Europe as determined by UQ and the Company. This process, resulting in the full grant of the Patent in each chosen territory, should take six to eight months.
 
Nigel Theobald, Chief Executive Officer of the Company, commented:
 
"The receipt of the intention to grant the primary Patent in respect of Nuvec® for Europe is a key milestone for the Company and should see other key jurisdictions where patents remain pending for Nuvec® follow suit. 
 
"The timing is especially relevant as we undertake our most comprehensive in vivo studies to date starting with Nuvec® loaded with the Coronavirus plasmid currently underway and the shortly to commence study incorporating our various learnings from the optimisation work over the last eighteen months.
 
"It is also particularly important as discussions with potential collaborators continue. We look forward to providing a full update on all our work streams, including our oral and oncology work, when we publish our full year results for the year ended 31 December 2020 which is expected to be towards the end of February / early March."
 
 
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.
 
Enquiries:
 



N4 Pharma plc








Nigel Theobald, CEO 


Via IFC Advisory




Luke Cairns, Executive Director


















SP Angel Corporate Finance LLP


Tel: +44(0)20 3470 0470




Nominated Adviser and Joint Broker








Matthew Johnson/Caroline Rowe (Corporate Finance)








Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)


















Turner Pope Investments (TPI) Limited


Tel: +44(0)20 3657 0050




Joint Broker








Andy Thacker/Zoe Alexander


















IFC Advisory Ltd
Financial PR
Graham Herring
Zach Cohen                                                  


Tel: +44(0)20 3934 6630



 
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCFLFLIFSILLIL